IP Library Granted Patent US 12,114,915
Granted Patent B2
US 12,114,915 · App. 18/612,572 · Granted Oct 15, 2024

Methods and systems for the treatment of polycystic ovary syndrome

Inventors: Denise Zarins (Saratoga, CA); Neil Barman (Menlo Park, CA); Garrett Schwab (Oakland, CA); Roger Osborne (La Honda, CA); Douglas Sutton (Pacifica, CA)
Assignee: May Health US Inc.
A61B18/1485A61B8/0841A61B8/085A61B8/12A61B18/1482A61F6/20A61B8/4427A61B8/4433A61B2017/00278A61B2017/003A61B2017/00455A61B17/22004A61B2017/3405A61B2017/3413A61B17/42A61B2017/4233A61B2018/00196A61B2018/00273A61B2018/00285A61B2018/00291A61B2018/00559A61B2018/00577A61B2018/00589A61B2018/00595A61B2018/00642A61B2018/00702A61B2018/0072A61B2018/00726A61B2018/00732A61B2018/00744A61B2018/00767A61B2018/00791A61B2018/00875A61B2018/00982A61B2018/0293A61B2018/048A61B18/06A61B18/1206A61B2018/143A61B2018/1432A61B2018/1475A61B18/16A61B18/22A61B2090/378A61B2090/3925A61B2090/3966A61N2007/0043A61N7/02A61N7/022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,114,915
App. No.
18/612,572
Granted
Oct 15, 2024
Kind
B2
Abstract

Described here are methods and systems for the manipulation of ovarian tissues. The methods and systems may be used in the treatment of polycystic ovary syndrome (PCOS). The systems and methods may be useful in the treatment of infertility associated with PCOS.

Claims (38)

1. A method for treating a patient with polycystic ovary syndrome, the method comprising:

advancing an elongated shaft of a device toward an ovary of the patient;

penetrating an ovarian wall of the ovary at a distal end of the elongated shaft;

positioning, via the elongated shaft, a therapeutic element of the device for delivering energy into the ovary; and

delivering the energy into tissue from inside the ovary using the therapeutic element to ablate a volume of the tissue ranging from 30 mm 3 to 3000 mm 3 within the ovary to treat anovulation associated with polycystic ovary syndrome (PCOS).

2. The method of claim 1 , wherein delivering the energy into the tissue comprises delivering radio frequency energy using the therapeutic element into the tissue.

3. The method of claim 1 , wherein delivering the energy into the tissue comprises delivering light-based energy using the therapeutic element into the tissue.

4. The method of claim 1 , wherein delivering the energy into the tissue comprises delivering ultrasound energy using the therapeutic element into the tissue.

5. The method of claim 1 , wherein delivering the energy into the tissue to ablate the volume of the tissue to treat anovulation treats infertility associated with PCOS.

6. The method of claim 1 , wherein penetrating the ovarian wall of the ovary comprises penetrating the ovarian wall at a single entry point.

7. The method of claim 1 , wherein the tissue within the ovary comprises a polycystic ovary.

8. The method of claim 1 , wherein delivering the energy into the tissue within the ovary comprises delivering energy for 20 to 60 seconds.

9. The method of claim 1 , wherein delivering the energy into the tissue reduces hormone levels or manipulates androgen levels, or both, to treat PCOS.

10. The method of claim 1 , wherein a total affected volume of the tissue ablated within the ovary is 240 mm 3 to 3000 mm 3 .

11. The method of claim 1 , wherein advancing the elongated shaft comprises advancing the elongated shaft into a vaginal canal, the method further comprising penetrating a vaginal wall via a needle tip at the distal end of the elongated shaft before penetrating the ovarian wall.

12. The method of claim 1 , wherein delivering the energy comprises delivering direct heating, cryoablation, cooling, laser, microwave, unfocused ultrasound, partially-focused ultrasound element, focused (HIFU) ultrasound, heated water/saline, steam, or chemical ablation energy.

13. The method of claim 1 , wherein delivering the energy into the tissue to ablate the volume of the tissue further treats at least one of acne, obesity, abdominal pain, hirsutism, or psychological symptoms associated with PCOS.

14. The method of claim 13 , further comprising imaging the ovary during an ablation procedure, wherein imaging the ovary comprises imaging the ovary via an ultrasound transducer in a field of view of the ultrasound transducer.

15. The method of claim 1 , wherein the volume of the tissue ablated is from a single actuation of ablation.

16. The method of claim 1 , further comprising, after delivering the energy, reorienting the therapeutic element within the ovary, and then delivering additional energy within the ovary via the therapeutic element for one or more additional deliveries of energy within the ovary to ablate the volume of the tissue ranging from 30 mm 3 to 3000 mm 3 within the ovary.

17. The method of claim 1 , further comprising removably coupling the device to a handle of a transvaginal ultrasound probe via an adapter configured to be removably coupled to the handle of the transvaginal ultrasound probe.

18. The method of claim 1 , wherein the therapeutic element comprises an active electrode and a return electrode.

19. The method of claim 1 , further comprising measuring temperature at the electrode during an ablation procedure.

20. The method of claim 1 , further comprising measuring tissue temperature during an ablation procedure.

21. The method of claim 20 , further comprising automatically terminating energy delivery if the measured tissue temperature exceeds a predetermined threshold.

22. The method of claim 1 , further comprising measuring tissue impedance during an ablation procedure.

23. The method of claim 1 , wherein the therapeutic element forms a curved configuration upon deployment from a lumen of the elongated shaft within the ovary.

24. The method of claim 1 , further comprising providing user input on duration of energy emission, power, target temperature, and/or mode of operation.

25. A method for treating a patient with polycystic ovary syndrome, the method comprising:

advancing an elongated shaft of a device toward an ovary of the patient;

penetrating an ovarian wall of the ovary at a distal end of the elongated shaft;

positioning, via the elongated shaft, a therapeutic element of the device for delivering energy into the ovary; and

delivering the energy into tissue from inside the ovary using the therapeutic element to ablate 3% to 20% of the tissue within the ovary to treat anovulation associated with polycystic ovary syndrome (PCOS).

26. The method of claim 25 , wherein delivering the energy into the tissue comprises delivering radio frequency energy using the therapeutic element into the tissue.

27. The method of claim 25 , wherein delivering the energy into the tissue comprises delivering light-based energy using the therapeutic element into the tissue.

28. The method of claim 25 , wherein delivering the energy into the tissue to ablate the volume of the tissue to treat anovulation treats infertility associated with PCOS.

29. The method of claim 25 , wherein delivering the energy into tissue reduces hormone levels or manipulates androgen levels, or both, to treat PCOS.

30. The method of claim 25 , further comprising, after delivering the energy, reorienting the therapeutic element within the ovary, and then delivering additional energy within the ovary via the therapeutic element for one or more additional deliveries of energy to ablate the 3% to 20% of the tissue within the ovary.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2024
From: ZARINS, DENISE; BARMAN, NEAL; OSBORNE, ROGER; SCHWAB, GARRETT; SUTTON, DOUGLAS
To: ZIVA MEDICAL, INC.
Reel/Frame 068497/0609 →
CHANGE OF NAME Recorded Sep 5, 2024
From: ZIVA MEDICAL, INC.
To: ABLACARE, INC.
Reel/Frame 068849/0022 →
CHANGE OF NAME Recorded Sep 5, 2024
From: ABLACARE, INC.
To: MAY HEALTH US INC.
Reel/Frame 068849/0074 →
Continuity (8)
Continuation 17192870 · Mar 4, 2021
Continuation 16819022 · Mar 13, 2020
Division 15494188 · Apr 21, 2017
Continuation 15094852 · Apr 8, 2016
Continuation PCTUS2014061159 · Oct 17, 2014
Provisional Application 61969042 · Mar 21, 2014
Provisional Application 61892943 · Oct 18, 2013
Related Publication 20240225723A1 · Jul 11, 2024
Cited By (1)
US 12,521,170